146 related articles for article (PubMed ID: 38180570)
21. Development and validation of a novel predictive scoring model for microvascular invasion in patients with hepatocellular carcinoma.
Zhao H; Hua Y; Dai T; He J; Tang M; Fu X; Mao L; Jin H; Qiu Y
Eur J Radiol; 2017 Mar; 88():32-40. PubMed ID: 28189206
[TBL] [Abstract][Full Text] [Related]
22. Preoperative estimation of the survival of patients with unresectable hepatocellular carcinoma achieving complete response after conventional transcatheter arterial chemoembolization: assessments of clinical and LI-RADS MR features.
Song W; Chen Q; Guo D; Jiang C
Radiol Med; 2022 Sep; 127(9):939-949. PubMed ID: 36018487
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of C-reactive protein in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Kaneko S; Asahina Y; Murakawa M; Ueyama S; Maeyashiki C; Watanabe H; Kusano-Kitazume A; Sato A; Uchidate K; Asakawa T; Watanabe S; Iizuka Y; Shibata I; Oooka S; Karakama Y; Fujii T; Watabe T; Akahoshi K; Tanabe M; Inada K; Mochida T; Watakabe K; Shimizu T; Tsuchiya J; Miyoshi M; Kitahata-Kawai F; Nitta S; Nakagawa M; Kakinuma S; Okamoto R;
Hepatol Res; 2023 Dec; ():. PubMed ID: 38133587
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
[TBL] [Abstract][Full Text] [Related]
25. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE.
Kong C; Zhao Z; Chen W; Lv X; Shu G; Ye M; Song J; Ying X; Weng Q; Weng W; Fang S; Chen M; Tu J; Ji J
Eur Radiol; 2021 Oct; 31(10):7500-7511. PubMed ID: 33860832
[TBL] [Abstract][Full Text] [Related]
26. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
27. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
28. Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma.
Lin CW; Chen YS; Lo GH; Wu TC; Yeh JH; Yeh ML; Dai CY; Huang JF; Chuang WL; Roberts L; Jun DW; Toyoda H; Yasuda S; Nguyen MH; Yu ML
Hepatol Int; 2021 Aug; 15(4):946-956. PubMed ID: 34008091
[TBL] [Abstract][Full Text] [Related]
29. A novel prognostic nomogram based on microvascular invasion and hematological biomarkers to predict survival outcome for hepatocellular carcinoma patients.
Li X; Huang H; Yu X; Chen P; Ouyang J; Huang B
Surg Oncol; 2020 Jun; 33():51-57. PubMed ID: 32561099
[TBL] [Abstract][Full Text] [Related]
30. Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI.
Sun Y; Bai H; Xia W; Wang D; Zhou B; Zhao X; Yang G; Xu L; Zhang W; Liu P; Xu J; Meng S; Liu R; Gao X
J Magn Reson Imaging; 2020 Oct; 52(4):1083-1090. PubMed ID: 32233054
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of prognostic nomograms in patients with hepatocellular carcinoma: a population-based study.
Zang Y; Long P; Wang M; Huang S; Chen C
Future Oncol; 2021 Dec; 17(36):5053-5066. PubMed ID: 34676798
[No Abstract] [Full Text] [Related]
32. Establishment of a predictive model for short-term efficacy of transcatheter arterial chemoembolization treatment in hepatocellular carcinoma and its clinical application.
Wei J; Wang Z
J Cancer Res Ther; 2019; 15(4):941-946. PubMed ID: 31436256
[TBL] [Abstract][Full Text] [Related]
33. Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy.
Guo DZ; Zhang SY; Dong SY; Yan JY; Wang YP; Cao Y; Rao SX; Fan J; Yang XR; Huang A; Zhou J
Front Immunol; 2023; 14():1141199. PubMed ID: 36911686
[TBL] [Abstract][Full Text] [Related]
34. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
35. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y
Front Immunol; 2022; 13():1013248. PubMed ID: 36466855
[TBL] [Abstract][Full Text] [Related]
36. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
37. Comparison of a preoperative MR-based recurrence risk score versus the postoperative score and four clinical staging systems in hepatocellular carcinoma: a retrospective cohort study.
Wei H; Jiang H; Qin Y; Wu Y; Lee JM; Yuan F; Zheng T; Duan T; Zhang Z; Qu Y; Chen J; Chen Y; Ye Z; Yao S; Zhang L; Yang T; Song B
Eur Radiol; 2022 Nov; 32(11):7578-7589. PubMed ID: 35554652
[TBL] [Abstract][Full Text] [Related]
38. Comparison of RETREAT and CCFSS Scoring Systems for Risk Estimation of Hepatocellular Carcinoma Recurrence After Radical Resection.
Zhang S; Zhang X; Mo C; Luo Y
Altern Ther Health Med; 2023 Nov; 29(8):694-698. PubMed ID: 37678878
[TBL] [Abstract][Full Text] [Related]
39. AGLR is a novel index for the prognosis of hepatocellular carcinoma patients: a retrospective study.
Liao Y; Wei R; Yao R; Qin L; Li J; Yu J; Liao W
BMC Surg; 2021 Feb; 21(1):72. PubMed ID: 33536005
[TBL] [Abstract][Full Text] [Related]
40. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.
Sun L; Mu L; Zhou J; Tang W; Zhang L; Xie S; Chen J; Wang J
Cancer Immunol Immunother; 2022 Jan; 71(1):25-38. PubMed ID: 33993366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
